Spero Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Spero Therapeutics Inc in the second quarter 2026?
Spero Therapeutics Inc achieved a return on average equity (ROE) of 16.17 % in its second quarter 2026, this is above SPRO's average return on equity of -65.7%.
Spero Therapeutics Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $46 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 41 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 306, from total ROE ranking in the first quarter 2026 at 309.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	34.65 %	56.54 %	27.96 %	-59.56 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	7	15	9	-44	-54
Return On Equity (TTM)	16.17 %	35.58 %	22.53 %	-125.91 %	-120.27 %
SPRO's Total Ranking	# 306	# 309	# 490	# 3277	# 2823
Equity (TTM) in Millions	44	53	59	26	33
Seq. Equity Change	-16.49 %	-10.31 %	122.77 %	-19.29 %	-2.92 %
Seq. Net Income Change	-	-	-	-	-

Back to SPRO Management Effectiveness >> SPRO's 5 Years Annual ROE >> Compare SPRO ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 42
Sector	# 104
Overall	# 306

Return On Equity Statistics
High	Average	Low
35.58 %	-65.7 %	-613.32 %
(Mar 31 2026)		(Mar 31 2018)

SPRO Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	59	46	107	76	88
Y / Y Equity Change	27.96 %	-56.85 %	40.77 %	-13.99 %	-33.13 %
Net Income in Millions	9	-69	23	-46	-90
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	14.52 %	-148.66 %	21.34 %	-61.13 %	-101.66 %

Back to SPRO Management Effectiveness >> SPRO's 5 Years Annual ROE >> Compare SPRO ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 14.52 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SPRO's' Return on Equity at Yahoo Finance
SPRO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SPRO's Competitors
Subscribers only: Roe for Spero Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for SPRO's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %
Chemed Corporation	29.45 %
Solventum Corporation	28.96 %
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %
Healthcare Services Group Inc	24.12 %
Electromed Inc	23.65 %
Iradimed Corporation	23.45 %
Vertex Pharmaceuticals Inc	23.31 %
Lantheus Holdings Inc	23.27 %
Msa Safety Inc	23.15 %
Prestige Consumer Healthcare Inc	21.77 %

Date modified: 2026-09-03T17:21:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.